U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06973564) titled 'JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration' on April 24.
Brief Summary: This study is to evaluate the safety and tolerability of JAB-23E73 in adult participants with advanced solid tumors
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: JAB-23E73
Oral administration
DRUG: JAB-23E73
Oral administration
DRUG: JAB-23E73
Oral administration
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....